Drug Trial Radar · NCT00235014
A Study for Prevention of Kidney Disease in Diabetic Patients (BENEDICT)
Last checked: Nov 20, 2026Latest source record: Jul 15, 2008 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,204
Actual
Start
Mar 1997
Primary completion
Jan 2006
Sponsor
- Lead sponsor
- AbbottIndustry
- Sponsor type
- Industry
- First posted
- Oct 10, 2005
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The BENEDICT study is conducted to examine the effects of an ACE inhibitor, calcium channel blockade, a combination of these, and placebo, in the prevention of micro- and macro-albuminuria in Type 2 diabetic patients.
Conditions
- Hypertension
- Diabetes
Interventions
trandolaprilDrug
2 mg QD
trandolapril/verapamilDrug
180/2 mg QD
placeboDrug
1 tablet QD
verapamilDrug
SR 240 mg QD
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase A: microalbuminuria; Phase B: progression from microalbuminuria to macroalbuminuria.Time frame: 3 years
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.